DIDESMETHYLROCAGLAMIDE
DIDESMETHYLROCAGLAMIDE 性质
沸点 | 691.4±55.0 °C(Predicted) |
---|---|
密度 | 1.379±0.06 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 二甲基亚砜:100 mg/mL(209.42 mM) |
形态 | 固体 |
酸度系数(pKa) | 11.70±0.70(Predicted) |
颜色 | 白色至米白色 |
DIDESMETHYLROCAGLAMIDE 用途与合成方法
Eukaryotic initiation factor 4A (eIF4A)
Didesmethylrocaglamide (5 nM, and 10 nM; 72 hours; MPNST cells) treatment arrests MPNST cells at G2-M, increases the sub-G1 population, induces cleavage of caspases and PARP, and elevates the levels of the DNA-damage response marker γH2A.X, while decreasing the expression of AKT and ERK1/2.
Didesmethylrocaglamide inhibits MPNST cell proliferation by inducing cell cycle arrest at G2/M and subsequently, cell death. Didesmethylrocaglamide-treated 697-R cells exhibits IC
50
values is very similar to those of parental 697 cells (4 vs 3nM of IC
50
, respectively).
Didesmethylrocaglamide induces apoptosis in both neurofibromatosis type 1 (NF1)-expressing and NF1-deficient MPNST cells, possibly subsequent to the activation of the DNA damage response. Didesmethylrocaglamide-treated sarcoma cells show decreased levels of multiple oncogenic kinases, including insulin-like growth factor-1 receptor.
Western Blot Analysis
Cell Line: | Malignant peripheral nerve sheath tumors (MPNST) cells |
Concentration: | 5 nM, and 10 nM |
Incubation Time: | 72 hours |
Result: | Induced cleavage of caspases and PARP, and elevated the levels of the DNA-damage response marker γH2A.X. |
DIDESMETHYLROCAGLAMIDE 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-19356A | 1 mg | 2600 | ||
2024-11-08 | HY-19356A | DIDESMETHYLROCAGLAMIDE | 177262-30-5 | 5mg | 5800 |